sanofi – Talk Bio

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

2 weeks ago talkbio0Tagged Amlitelimab, Dermatitis, Atopic, Dupixent, EASI-75, Eczema, Expectations, Market, Reaction, sanofi

Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction

Sanofi’s Wayrilz Receives FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

2 weeks ago talkbio0Tagged Approved, Autoimmune thrombocytopenia, BTK inhibitor, Inosine Triphosphate, LUNA 3 trial, Rilzabrutinib, sanofi, United States Food and Drug Administration, Wayrilz

Wayrilz; rilzabrutinib; FDA approval; immune thrombocytopenia; ITP; BTK inhibitor; Sanofi; LUNA 3 trial

Sanofi Contributes to Report Emphasizing Importance of Sustainably Paid Community Health Workers

3 weeks ago talkbio0Tagged Advocacy, CHW Access Act, Community Health Workers, digital infrastructure, Health Equity, National Association of, Policy, sanofi, sustainability

Sanofi; community health workers; sustainability; health equity; National Association of Community Health Workers; policy advocacy; digital infrastructure; CHW Access Act

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

1 month ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

2 months ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

Thermo Fisher to Acquire Sanofi Factory; Amphastar Plans Major HQ Expansion

2 months ago talkbio0Tagged Acquisition, Amphastar, California, capacity quadruple, expansion, fill-finish, headquarters, pharmaceutical manufacturing, Ridgefield New Jersey, sanofi, sterile manufacturing, Thermo Fisher

Thermo Fisher; Sanofi; acquisition; sterile manufacturing; Ridgefield New Jersey; fill-finish; pharmaceutical manufacturing; Amphastar; headquarters expansion; capacity quadruple; California

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

3 months ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

3 months ago talkbio0Tagged CDK2 protein, human, Gilead, Kymera, Molecular Glue Degrader, Neoplasms, protein degrader, sanofi

Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

3 months ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

3 months ago talkbio0Tagged Approved, Autoimmune Diseases, Bullous pemphigoid, Drugs, Orphan, dupilumab, Dupixent, Priority Review, Regeneron, sanofi, type 2 inflammation, United States Food and Drug Administration

Dupixent; Dupilumab; Sanofi; Regeneron; bullous pemphigoid; FDA approval; type 2 inflammation; autoimmune disease; priority review; orphan drug